FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says
December 07, 2011
FDA/CMS Parallel Review of Medical Products Limited Only by Sponsors' Reluctance, CMS Official Says
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- With Top-line Deep-C Trial Data, Exact Sciences Gears Up for FDA and CMS Submissions for Cologuard
April 24, 2013 / Pharmacogenomics Reporter - Exact Sciences Discusses Benefits of Taking Cologuard through FDA/CMS Parallel Review Pilot
April 3, 2013 / Pharmacogenomics Reporter - Palmetto Issuing 'Z-Codes' to Track Molecular Dx Utilization, Gather Data CPT Codes Can't Provide
November 16, 2011 / Pharmacogenomics Reporter - FDA, CMS Parallel Review Pilot Opens Opportunities for Personalized Medicine Molecular Dx
October 12, 2011 / Pharmacogenomics Reporter - FDA Shelves IVDMIA Final Guidelines in Order to Focus on Overall LDT Regulation
June 23, 2010 / Pharmacogenomics Reporter